Pasireotide LAR and Pegvisomant Study in Acromegaly
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the efficacy of Pasireotide Long Acting Release
(LAR) alone and in combination with weekly Pegvisomant (PEGV) in acromegaIy patients
previously controlled with combination treatment of long-acting Somatostatin analogs
(LA-SSAs) and PEGV.